Literature DB >> 18430387

Medication-induced osteoporosis.

Meng-Yi Weng1, Nancy E Lane.   

Abstract

Osteoporosis, a condition of low bone mass and microarchitectural deterioration, results in fractures with minimal trauma. Secondary osteoporosis is defined as bone loss resulting from either specific clinical disorders or medications. Some medications that can induce osteoporosis are discussed. Specifically, this article reviews the pathogenesis of glucocorticoid-induced bone loss and demonstrates the means to successfully manage the condition with a combination of calcium and vitamin D supplementation and, depending on the severity of the bone loss, bisphosphonates or parathyroid hormone. In addition, the pathophysiology of bone loss from aromatase inhibitors in women, gonadotropin-releasing hormone agonists in men, anticonvulsant medications, and proton pump inhibitors is outlined. Finally, this review offers suggestions on evaluation and management of bone health in individuals treated with these medications for prolonged times.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18430387     DOI: 10.1007/s11914-007-0008-y

Source DB:  PubMed          Journal:  Curr Osteoporos Rep        ISSN: 1544-1873            Impact factor:   5.096


  50 in total

Review 1.  Corticosteroids and fractures: a close encounter of the third cell kind.

Authors:  S C Manolagas
Journal:  J Bone Miner Res       Date:  2000-06       Impact factor: 6.741

2.  Inhaled corticosteroids: benefits and risks.

Authors:  D M Geddes
Journal:  Thorax       Date:  1992-06       Impact factor: 9.139

Review 3.  The science and therapy of glucocorticoid-induced bone loss.

Authors:  N E Lane; B Lukert
Journal:  Endocrinol Metab Clin North Am       Date:  1998-06       Impact factor: 4.741

4.  Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

Authors:  S Cohen; R M Levy; M Keller; E Boling; R D Emkey; M Greenwald; T M Zizic; S Wallach; K L Sewell; B P Lukert; D W Axelrod; A A Chines
Journal:  Arthritis Rheum       Date:  1999-11

Review 5.  The diagnosis and treatment of osteoporosis in men on androgen deprivation therapy for advanced carcinoma of the prostate.

Authors:  David C Bae; Barry S Stein
Journal:  J Urol       Date:  2004-12       Impact factor: 7.450

6.  Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer.

Authors:  Matthew R Smith; Simone Peart Boyce; Erick Moyneur; Mei Sheng Duh; Monika K Raut; Jane Brandman
Journal:  J Urol       Date:  2006-01       Impact factor: 7.450

7.  Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.

Authors:  Michael F X Gnant; Brigitte Mlineritsch; Gero Luschin-Ebengreuth; Stephan Grampp; Helmut Kaessmann; Marianne Schmid; Christian Menzel; Jutta Claudia Piswanger-Soelkner; Arik Galid; Martina Mittlboeck; Hubert Hausmaninger; Raimund Jakesz
Journal:  J Clin Oncol       Date:  2006-12-11       Impact factor: 44.544

8.  Bone mineral density in asthmatic women on high-dose inhaled beclomethasone dipropionate.

Authors:  J Herrala; H Puolijoki; O Impivaara; K Liippo; E Tala; M M Nieminen
Journal:  Bone       Date:  1994 Nov-Dec       Impact factor: 4.398

9.  Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.

Authors:  K G Saag; R Emkey; T J Schnitzer; J P Brown; F Hawkins; S Goemaere; G Thamsborg; U A Liberman; P D Delmas; M P Malice; M Czachur; A G Daifotis
Journal:  N Engl J Med       Date:  1998-07-30       Impact factor: 91.245

10.  Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

Authors:  M Dror Michaelson; Donald S Kaufman; Hang Lee; Francis J McGovern; Philip W Kantoff; Mary Anne Fallon; Joel S Finkelstein; Matthew R Smith
Journal:  J Clin Oncol       Date:  2007-03-20       Impact factor: 44.544

View more
  9 in total

Review 1.  Skeletal Implications of Chronic Obstructive Pulmonary Disease.

Authors:  Barbara M Misof; Carolina A Moreira; Klaus Klaushofer; Paul Roschger
Journal:  Curr Osteoporos Rep       Date:  2016-04       Impact factor: 5.096

2.  Simvastatin attenuates TNF-alpha-induced growth inhibition and apoptosis in murine osteoblastic MC3T3-E1 cells.

Authors: 
Journal:  Inflamm Res       Date:  2010-02       Impact factor: 4.575

3.  Bone: serotonin, leptin and the central control of bone remodeling.

Authors:  Clifford J Rosen
Journal:  Nat Rev Rheumatol       Date:  2009-12       Impact factor: 20.543

Review 4.  The genetics of bone loss: challenges and prospects.

Authors:  Braxton D Mitchell; Laura M Yerges-Armstrong
Journal:  J Clin Endocrinol Metab       Date:  2011-02-23       Impact factor: 5.958

5.  Cortical bone quality affectations and their strength impact analysis using holographic interferometry.

Authors:  Cesar G Tavera Ruiz; Manuel H De La Torre-Ibarra; J M Flores-Moreno; Claudio Frausto-Reyes; Fernando Mendoza Santoyo
Journal:  Biomed Opt Express       Date:  2018-09-14       Impact factor: 3.732

6.  Adherence to treatment with selective serotonin reuptake inhibitors and the risk for fractures and bone loss: a population-based cohort study.

Authors:  Inbar Zucker; Gabriel Chodick; Leon Grunhaus; Ra'anan Raz; Varda Shalev
Journal:  CNS Drugs       Date:  2012-06-01       Impact factor: 5.749

Review 7.  Diseases affecting bone quality: beyond osteoporosis.

Authors:  Aasis Unnanuntana; Brian J Rebolledo; M Michael Khair; Edward F DiCarlo; Joseph M Lane
Journal:  Clin Orthop Relat Res       Date:  2011-08       Impact factor: 4.176

8.  Walk on the sunny side of life--epidemiology of hypovitaminosis D and mental health in elderly nursing home residents.

Authors:  V Verhoeven; K Vanpuyenbroeck; M Lopez-Hartmann; J Wens; R Remmen
Journal:  J Nutr Health Aging       Date:  2012-04       Impact factor: 4.075

Review 9.  Dental implants in Sjögren's syndrome patients: A systematic review.

Authors:  Daniel Almeida; Katia Vianna; Patrícia Arriaga; Vittorio Moraschini
Journal:  PLoS One       Date:  2017-12-14       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.